JP2024517546A5 - - Google Patents

Info

Publication number
JP2024517546A5
JP2024517546A5 JP2023555342A JP2023555342A JP2024517546A5 JP 2024517546 A5 JP2024517546 A5 JP 2024517546A5 JP 2023555342 A JP2023555342 A JP 2023555342A JP 2023555342 A JP2023555342 A JP 2023555342A JP 2024517546 A5 JP2024517546 A5 JP 2024517546A5
Authority
JP
Japan
Prior art keywords
reuteri
probiotic
dsm
gos
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517546A (ja
Filing date
Publication date
Priority claimed from EP21162450.7A external-priority patent/EP4056052A1/en
Application filed filed Critical
Publication of JP2024517546A publication Critical patent/JP2024517546A/ja
Publication of JP2024517546A5 publication Critical patent/JP2024517546A5/ja
Pending legal-status Critical Current

Links

JP2023555342A 2021-03-12 2022-03-11 最終製剤中のgosプレコンディショニングl.ロイテリ(l.reuteri)及びgos Pending JP2024517546A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21162450.7A EP4056052A1 (en) 2021-03-12 2021-03-12 Gos pre-conditioning l. reuteri and gos in final formulation
EP21162450.7 2021-03-12
PCT/SE2022/050245 WO2022191767A1 (en) 2021-03-12 2022-03-11 Gos pre-conditioning l. reuteri and gos in final formulation

Publications (2)

Publication Number Publication Date
JP2024517546A JP2024517546A (ja) 2024-04-23
JP2024517546A5 true JP2024517546A5 (https=) 2025-03-11

Family

ID=74873671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555342A Pending JP2024517546A (ja) 2021-03-12 2022-03-11 最終製剤中のgosプレコンディショニングl.ロイテリ(l.reuteri)及びgos

Country Status (7)

Country Link
US (1) US20230405062A1 (https=)
EP (2) EP4056052A1 (https=)
JP (1) JP2024517546A (https=)
CN (1) CN117460428A (https=)
CA (1) CA3205769A1 (https=)
MX (1) MX2023009930A (https=)
WO (1) WO2022191767A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116806965A (zh) * 2023-03-10 2023-09-29 内蒙古大学 用于补钙成骨的益生菌骨粉发酵液及其制备方法、用途
CN116814503B (zh) * 2023-07-27 2024-01-30 山东奈思健康科技有限责任公司 一种促补钙护骨的后生元制品及其制备方法和应用
WO2025078557A1 (en) 2023-10-11 2025-04-17 Société des Produits Nestlé S.A. Compositions comprising a probiotic strain for improving muscle strength
CN118726137B (zh) * 2024-06-06 2025-03-25 科为生物(镇江)有限公司 一株可拮抗幽门螺杆菌和修复黏膜屏障损伤的罗伊氏粘液乳杆菌MeetU及其应用
CN120192865A (zh) * 2024-11-07 2025-06-24 河北农业大学 一种罗伊氏粘液乳杆菌mry6及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688538T3 (es) 2010-12-23 2018-11-05 Dupont Nutrition Biosciences Aps Composiciones crioprotectoras y uso de las mismas
US20120263696A1 (en) * 2011-04-14 2012-10-18 Stefan Roos Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol
EP2677886A4 (en) * 2011-02-23 2015-09-02 Biogaia Ab INDIRECT SUBSTRATES FOR MICRO-ORGANISMS FOR THE METABOLIZATION OF 1,2-PROPANDIOL
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
EP3016511B1 (en) 2013-07-02 2019-10-09 Austrianova Singapore Pte Ltd. A method of freeze-drying encapsulated cells, compositions suitable for freezing of encapsulated cells and use of such compositions
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
WO2017001590A1 (en) 2015-06-30 2017-01-05 Nestec S.A. Composition suitable for protecting microorganisms
MX2019014315A (es) * 2017-08-04 2020-02-03 Nestle Sa Bacterias probioticas preacondicionadas en un medio que contiene gos y uso de estas.
AU2020218748B2 (en) * 2019-02-05 2023-12-21 Biomedit, Llc A genetically modified lactobacillus and uses thereof

Similar Documents

Publication Publication Date Title
JP2024517546A5 (https=)
Saleem et al. Therapeutic potential of popular fermented dairy products and its benefits on human health
US10501530B2 (en) Probiotics, secretory IgA and inflammation
JP5709883B2 (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
AU2007292786B2 (en) Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor
CN117460428A (zh) Gos预调理的罗伊氏乳杆菌和最终制剂中的gos
WO2021235486A1 (ja) 腸管発達促進用組成物、肺機能改善用組成物および免疫機能向上用組成物
JP6491422B2 (ja) 免疫疾患予防剤
JP2018177703A (ja) Toll様受容体2活性化用組成物
JP2024517547A5 (https=)
JP6821643B2 (ja) 免疫疾患予防剤
JP2024517547A (ja) L.ロイテリ(l.reuteri)のプレコンディショニング
WO2017103072A1 (en) Microparticles for encapsulating probiotics, obtaining said microparticles and uses thereof
JP5209294B2 (ja) インターロイキン12産生促進剤
JP7539163B2 (ja) ビフィドバクテリウム・ビフィダム非生菌及びその使用
CN109803668A (zh) 用于抑制肠道内乳杆菌属乳酸菌减少的组合物
JP7533830B2 (ja) 破骨前駆細胞の破骨細胞への分化抑制用組成物及び骨代謝改善用組成物
Desai et al. of Probiotics for Wellness in Elderly Populations
Chavda et al. A Glance to the Patent World of Probiotics 15
TW202228751A (zh) 益生元組合物及木豆屬組合物用於調整腸胃道菌相之用途
JP2012136450A (ja) インフルエンザウイルス感染予防用組成物
Al-Nabulsi et al. Health Benefits of Symbiotic Functional Food Products